NCT01841489已完成1 期
A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Pharmacokinetic parameters for GS-9973
研究概览
简要总结
This is a Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
- •Must have a body mass index (BMI) range of approximately 19 to 30 kg/m2
- •Must have a minimum weight of 45 kg
- •Females of childbearing potential must have negative serum pregnancy tests at screening and baseline and must practice at least 1 reliable method of contraception as defined by the protocol
- •Female subjects who utilize hormonal contraceptive as 1 of their birth control methods must have used the same method for at least 3 months prior to study dosing
- •Male subjects must agree to use condoms during heterosexual intercourse and avoid sperm donation from Day -1 until 90 days following the last dose of study medication
- •Must refrain from blood donation throughout the study period
- •Must, in the opinion of the Investigator, be in good general
- •Must be a non- or light smoker, eg, less than 10 cigarettes per day
排除标准
- •Pregnant or lactating subjects
- •Use of prescribed or over-the-counter medications that affect gastric pH
- •History of severe peptic ulcer disease, GERD, or other diseases requiring prolonged(>6 weeks) medication or surgical therapy to modify gastric pH
- •Have a history of clinically significant cardiac abnormalities or presence of clinically significant abnormality on 12-lead ECG.
- •Have a history of any cancer requiring systemic chemotherapy or radiation
- •Have a history of bleeding disorders
- •Have a history of liver disorders
- •Current acute infection or history of acute infection within 7 days
- •Have a recent history of alcohol or illicit drug abuse and/or have a positive test for selected drugs of abuse
- •Have a positive hepatitis screen or positive Human Immunodeficiency Virus antibody test
- •Have participated in another clinical trial within 28 days
- •Have received transfusion of blood or plasma products within 6 months
- •Have donated > 500 mL blood within 56 days
- •Are unable or unwilling to comply with study restrictions, return for follow-up appointments, or other considerations, which in the opinion of the Investigator, would make the candidate unsuitable for study participation
- •Current or historical medical condition that is deemed to be of medical significance by the Investigator
- •Have used prescription medications, over the counter products, herbal remedies and nutritional supplements within 7 days
研究组 & 干预措施
Sequence 1
Experimental
干预措施: Treatment A (Drug)
Sequence 1
Experimental
干预措施: Treatment B (Drug)
Sequence 1
Experimental
干预措施: Treatment G (Drug)
Sequence 1
Experimental
干预措施: Treatment I (Drug)
Sequence 2
Experimental
干预措施: Treatment A (Drug)
Sequence 2
Experimental
干预措施: Treatment C (Drug)
Sequence 2
Experimental
干预措施: Treatment H (Drug)
Sequence 2
Experimental
干预措施: Treatment J (Drug)
Sequence 3
Experimental
干预措施: Treatment D (Drug)
Sequence 3
Experimental
干预措施: Treatment E (Drug)
Sequence 3
Experimental
干预措施: Treatment G (Drug)
Sequence 3
Experimental
干预措施: Treatment I (Drug)
Sequence 4
Experimental
干预措施: Treatment D (Drug)
Sequence 4
Experimental
干预措施: Treatment F (Drug)
Sequence 4
Experimental
干预措施: Treatment H (Drug)
Sequence 4
Experimental
干预措施: Treatment J (Drug)
结局指标
主要结局
Pharmacokinetic parameters for GS-9973
时间窗: Up to 3 months
The primary outcome measure is the pharmacokinetic (PK) parameters for GS-9973 including AUC and Cmax.
次要结局
- Incidence of Adverse Events(Up to 3 months)
- Secondary pharmacokinetic parameters for GS-9973(Up to 3 months)
- Blood PD parameters for GS-9973(Up to 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy ParticipantsNeoplasm, Advanced or MetastaticNCT02625259Millennium Pharmaceuticals, Inc.54
已完成
1 期
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid TumorsNeoplasmsNCT03447314GlaxoSmithKline54
已完成
1 期
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid TumorsSolid TumorNCT02048709Genentech, Inc.22
已完成
1 期
Bioavailability Study With GLPG1972OsteoarthritisNCT02851485Galapagos NV12
撤回
2 期
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaCancerNCT01445587GlaxoSmithKline